This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by De Falco, V. Articles by Melillo, R. M. Search for Related Content PubMed PubMed Citation Articles by De Falco, V. Articles by Melillo, R. M.

Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer

¹ Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR "G. Salvatore," Facolta' di Medicina e Facolta' di Scienze Biotecnologiche dell‘Universita’ "Federico II"; ² Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, Universita' "Parthenope," Naples, Italy; and ³ Dipartimento di Chirurgia, Universita' di Pisa, Pisa, Italy

Requests for reprints: Rosa Marina Melillo, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, via S. Pansini 5, 80131 Naples, Italy. Phone: 39-081-7463603; Fax: 39-081-7463603; E-mail: rosmelil{at}unina.it.

Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer type with an extremely poor prognosis. Despite appropriate treatment, which includes surgery, radiotherapy, and chemotherapy, this cancer is invariably fatal. CXCR4 is the receptor for the stromal cell–derived factor-1 (SDF-1)/CXCL12 chemokine and it is expressed in a variety of solid tumors, including papillary thyroid carcinoma. Here, we show that ATC cell lines overexpress CXCR4, both at the level of mRNA and protein. Furthermore, we found that CXCR4 was overexpressed in ATC clinical samples, with respect to normal thyroid tissues by real-time PCR and immunohistochemistry. Treatment of ATC cells with SDF-1 induced proliferation and increase in phosphorylation of extracellular signal–regulated kinases and protein kinase B/AKT. These effects were blocked by the specific CXCR4 antagonist AMD3100 and by CXCR4 RNA interference. Moreover, AMD3100 effectively reduced tumor growth in nude mice inoculated with different ATC cells. Thus, we suggest that CXCR4 targeting is a novel potential strategy in the treatment of human ATC. [Cancer Res 2007;67(24):11821–9]